PMP™ was used in a recent study to explore the gut microbiome of children with inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children. Diagnostic, Phenotype and Prognostic Indexes were constructed based on PMP™ data with very good discriminating properties....
Bio-Me has employed Dr. Anne-Grethe Reichelt as part of the company’s plan to widen commercial adoption of their existing product portfolio and launch new products under development. ...
Bio-Me has joined the Medicen Working Group, an international initiative focusing on drug-microbiome interactions. The aim of the group is to accelerate the microbiome integration in the drug discovery and development process....
PMP™ has shown its applicability in obesity research in a study published in The Lancet. More than 5000 fecal samples from the HUNT Biobank in Norway were analyzed with PMP™....
Bio-Me has joined MTIG. Group members work together to accelerate microbiome-based drug development and expand availability of approved microbiome therapies to patients....
Bio-Me has appointed a new CEO as part of the company’s strategic plan to be positioned as a leader in the microbiome-based Precision Medicine space....
Our COO, Warren Flood, will be participating in a webinar together with Thermo Fisher Scientific on September 22nd with a focus on our PMP™ technology and its applicability....
Bio-Me has announced a major board restructuring that will support the Company during its new phase of development....
Bio-Me has been invited to present at the upcoming Microbiome Movement - Drug Development Summit. ...
Bio-Me and Akershus University Hospital aim to explore gut microbiome profiles linked to long-term effects of COVID-19....
